August 2009
Volume 9, Issue 8
Free
Vision Sciences Society Annual Meeting Abstract  |   August 2009
Efficacy of NeuroVision's NVC™ technology treatment on unaided visual acuity in moderate myopes
Author Affiliations
  • Sheng Tong Lin
    Defence Medical & Environmental Research Institute, DSO National Laboratories, Singapore
  • Adeline Yang
    Defence Medical & Environmental Research Institute, DSO National Laboratories, Singapore
  • Jolene Ong
    Singapore Eye Research Institute, Singapore
  • Gerard Nah
    Military Medicine Institute, Singapore Armed Forces, Singapore
  • Lionel Lee
    Defence Medical & Environmental Research Institute, DSO National Laboratories, Singapore
  • Donald Tan
    Singapore National Eye Centre, Singapore
Journal of Vision August 2009, Vol.9, 1051. doi:10.1167/9.8.1051
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sheng Tong Lin, Adeline Yang, Jolene Ong, Gerard Nah, Lionel Lee, Donald Tan; Efficacy of NeuroVision's NVC™ technology treatment on unaided visual acuity in moderate myopes. Journal of Vision 2009;9(8):1051. doi: 10.1167/9.8.1051.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

NeuroVision's NVC™ vision correction is a non-invasive treatment based on visual stimulation and facilitation of neural connections responsible for vision. This treatment involves an internet-based computer generated visual training exercise regime using sets of patient-specific stimuli (Gabor patches) to sharpen contrast sensitivity function (CSF) and visual acuity (VA). The reported treatment successes were mainly in low myopes (−0.50DS to −1.50DS). This study is a pioneering effort to evaluate the efficacy of NeuroVision's treatment for unaided VA (UCVA) improvement in moderate myopes (−1.75DS to −3.00DS). 102 moderate myopes were given NeuroVision treatment, while another 35 subjects in a control group were given placebo treatment resembling the NeuroVision treatment in a superficial way. Each subject completed 40 sessions of treatment within 3 months. The end-of-treatment examination indicated a mean UCVA improvement of 0.17(+/−0.01) LogMAR for the treatment group and 0.10(+/−0.03) LogMAR for the placebo group. In addition, 58% of the treatment group and 42% of the control group have 0.2 LogMAR or more UCVA improvement in at least one eye. Nevertheless, the difference between the two percentages was not significant (P[[gt]]0.05, Fisher's Exact Test). However, after one year without further treatments, post-treatment examinations revealed strong retention of UCVA improvements in the treatment group but not in the control group; the treatment group still retained a mean UCVA improvement of 0.14(+/−0.01) LogMAR, while the mean control group improvements dipped to 0.05(+/−0.02) LogMAR. Moreover, 50% of the treatment group retained 0.2 LogMAR or more UCVA improvement in at least one eye after one year, significantly greater than the 24% observed in the control (P=0.01, Fisher's Exact Test). The retention results indicated that NeuroVision's NVC vision correction produced a stable one year post-treatment improvement in UCVA for moderate myopes.

Lin, S. T. Yang, A. Ong, J. Nah, G. Lee, L. Tan, D. (2009). Efficacy of NeuroVision's NVC™ technology treatment on unaided visual acuity in moderate myopes [Abstract]. Journal of Vision, 9(8):1051, 1051a, http://journalofvision.org/9/8/1051/, doi:10.1167/9.8.1051. [CrossRef]
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×